Treatment courses often total $800 to $1,500
June 2024: Structure Therapeutics reported positive Phase IIa obesity data for GSBR-1290, an oral non-peptide small-molecule GLP-1 receptor agonist, achieving 6.2% placebo-adjusted mean weight loss at 12 weeks
Examples that may be considered in certain plans: NAD+ support strategies when cellular energy regulation is part of the picture Thymosin-class peptides (such as Thymosin Alpha-1 or Thymosin Beta-4) in immune modulation discussions (case-dependent) GHK-Cu when skin and connective tissue signaling is a parallel priority Sleep-focused lifestyle and nutrient review because peptides do not compensate for chronic sleep disruption drivers More compounds is not automatically better
J Clin Endocrinol Metab (1996) 81(2):4605.10.1210/jcem.81.2.8636250 246 LiuHBravataDMOlkinINayakSRobertsBGarberAMet alSystematic review: the safety and efficacy of growth hormone in the healthy elderly
However, in recent years, Ozempic and other GLP-1 drugs have been linked to a number of gastrointestinal problems, including gastroparesis, known as stomach paralysis, and bowel obstructions
During your consultation, Dr Edwin will assess your suitability and recommend the most appropriate starting dose and gradual increase schedule based on your individual weight loss goals and health profile